Multiple sclerosis, adherence, compliance, glatiramer acetate
Conditions
Interventions
None listed
Sponsors
MS4 Research Institute,
Ubbergseweg 34,
6522 KJ Nijmegen,
the Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: 1. Indication for GA treatment in Relapsing Remitting MS (RRMS), as formulated by the regulatory authorities in the Netherlands; 2. Being relapse free and having stable symptoms for at least 30 days; 3. Willing and able to comply with the protocol for the duration of the study; 4. Having given written informed consent prior to any study-related procedure not part of standard neurological practice, with the understanding that the consent may be withdrawn by the patient at any time without prejudice to his/her neurological care.
Exclusion criteria
Exclusion criteria: 1. Contra-indications for GA as defined in the Summary of Product Characteristics text; 2. Hypersensitivity to glatiramer acetate or mannitol; 3. Worsening of symptoms suggestive of relapse; 4. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcomes are correlations between: 1. Numbers of missed doses's; 2. Numbers of patients who discontinued GA treatment; 3. Numbers of care sessions's; 4. Duration of care per modality. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are (cor)relations between: 1. Number of missed doses's; 2. Numbers of patients who discontinued GA treatment; 3. Presence's; 4. Degree of socio-economic, health care, caregivers, disease, treatment and patient characteristics. | — |
Contacts
Public ContactPeter Joseph Jongen
Ubbergseweg 34
Outcome results
None listed